Peptide Stack Generator

Predominantly preclinical/animal studies; human data is limited to small, older trials and case reports.

FDA-approved (Vyleesi) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Showed promise in early male ED trials but not FDA-approved for men.

Case studies and anecdotal reports for erectile function and libido; no rigorous RCTs.

Preclinical and small cosmetic studies suggest stimulation of hair growth and follicle enlargement; robust clinical trials vs minoxidil/finasteride are lacking.

Small Russian clinical trials suggest anxiolytic effects, possibly via modulation of GABA and monoamine systems. No large international RCTs.

Very limited clinical data specifically for depression; some Russian studies suggest mood stabilization in anxiety-depressive disorders.

Primarily studied for cognitive/neuroprotective effects in Russia; direct evidence for major depressive disorder is sparse.

Multiple meta-analyses and systematic reviews show small-to-moderate cognitive benefits in vascular dementia and Alzheimer's disease. Used clinically in some European and Asian countries.

Russian clinical studies suggest benefits in cognitive impairment after stroke and in optic nerve atrophy; no large Western RCTs.

Preclinical only. Angiotensin IV analog with procognitive properties in rodent models of neurodegeneration; one recent study showed no benefit in a Huntington's model.

Extensive preclinical (animal) data for tendon, ligament, muscle, and gastric injury. No published peer-reviewed human clinical trials.

Preclinical studies support wound healing and tissue repair. Limited early-phase human trials showed some signal but were small.

Shown to accelerate wound healing and tissue repair in animal models and some small human skin studies.

FDA-approved (Egrifta) for HIV-associated lipodystrophy. Increases IGF-1 and lean body mass in HIV-infected patients with central fat accumulation.

Growth hormone secretagogues studied in small trials; robust RCTs for sarcopenia are lacking.

FDA-approved (Wegovy for obesity; Ozempic for T2D). Large RCTs (STEP program) demonstrate 10-15% body weight loss.

FDA-approved (Zepbound for obesity; Mounjaro for T2D). Dual GIP/GLP-1 agonist. Large RCTs show up to 20% weight loss.

FDA-approved (Saxenda for obesity; Victoza for T2D). Earlier-generation GLP-1 agonist with robust RCT evidence (SCALE trials).

Small Russian and Ukrainian clinical trials suggest normalization of melatonin rhythms and potential telomerase activation. No large international RCTs.

Preclinical work on gene expression resetting and tissue repair; no clinical longevity trials.

FDA-approved (Gattex) for short bowel syndrome (SBS) dependent on parenteral support. GLP-2 analog that improves intestinal absorption.

Extensive animal data for gastric ulcer, inflammatory bowel disease models, and intestinal healing. No human clinical trials.

Approved in some countries for hepatitis B/C and as an immunomodulator. Evidence from oncology and infectious disease settings suggests immune enhancement. Not FDA-approved in the US.

Thymic peptide used in Russian geriatric practice; small studies suggest immune modulation in elderly.

Alpha-MSH fragment with anti-inflammatory effects in colitis and dermatitis animal models. No human clinical trials.

Animal studies show anti-inflammatory effects in multiple models (gut, joint, tendon). No human trials.

Small human trials and extensive cosmetic use suggest improved skin elasticity, firmness, and wrinkle reduction. Mechanism involves collagen synthesis and matrix remodeling.

In-vitro and small cosmetic studies show stimulation of collagen I, fibronectin, and hyaluronic acid. Large clinical trials are lacking.

FDA granted accelerated approval (September 2025) for Barth syndrome. Mitochondria-targeted peptide that binds cardiolipin.

Mitochondrial-derived peptide. Preclinical and very limited human data suggest metabolic benefits and exercise mimetic effects. No robust RCTs for fatigue.

Mixed evidence. Some earlier RCTs and meta-analyses reported modest pain reduction in knee osteoarthritis, but a recent rigorous RCT (2025) found combined UC-II and hydrolyzed collagen no better than placebo.

Strong animal data for tendon, ligament, and joint healing. No human clinical trials.

FDA-approved (Factrel) for evaluating hypothalamic-pituitary-gonadal axis function. Can stimulate endogenous testosterone production in hypogonadotropic hypogonadism.

Clinical trials demonstrate that kisspeptin stimulates GnRH and subsequent LH/testosterone secretion in men, including those with hypogonadism.

Meta-analyses indicate small-to-moderate benefits in vascular dementia and Alzheimer's disease, particularly on global cognition and functional outcomes.

Russian clinical studies in vascular dementia and post-stroke cognitive impairment suggest memory and attention benefits.

Small Russian trials suggest reduction of stress-related symptoms and anxiety, possibly through enkephalinase inhibition and GABA modulation.

No human clinical trials for athletic performance or recovery. Animal studies suggest accelerated healing of tendon, muscle, and bone injuries.

Preclinical and limited early human data on wound healing. No rigorous RCTs for athletic recovery.

Non-erythropoietic erythropoietin analog. Small Phase 2 trials in neuropathy and sarcoidosis-related fatigue.